ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AGEN Agenus Inc

0.5721
0.0157 (2.82%)
After Hours
Last Updated: 16:23:17
Delayed by 15 minutes

Period:

Draw Mode:

Volume 5,492,624
Bid Price 0.5722
Ask Price 0.5798
News -
Day High 0.574

Low
0.485

52 Week Range

High
2.13

Day Low 0.5505
Company Name Stock Ticker Symbol Market Type
Agenus Inc AGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0157 2.82% 0.5721 16:23:17
Open Price Low Price High Price Close Price Prev Close
0.5564 0.5505 0.574 0.5733 0.5564
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
8,758 5,492,624 $ 0.5643095 $ 3,099,540 - 0.485 - 2.13
Last Trade Time Type Quantity Stock Price Currency
16:28:16 2 $ 0.5723 USD

Agenus Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
238.78M 418.92M - 98.84M -220.29M -0.53 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Agenus News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AGEN Message Board. Create One! See More Posts on AGEN Message Board See More Message Board Posts

Historical AGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.55160.57970.5250.55186044,968,8430.02053.72%
1 Month0.7360.77630.4850.61727657,953,960-0.1639-22.27%
3 Months0.780.9490.4850.666778910,525,347-0.2079-26.65%
6 Months1.171.170.4850.72708029,814,674-0.5979-51.10%
1 Year1.602.130.4851.007,307,161-1.03-64.24%
3 Years2.886.790.4852.185,431,144-2.31-80.14%
5 Years2.896.790.4852.464,072,272-2.32-80.20%

Agenus Description

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.

Your Recent History

Delayed Upgrade Clock